These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 19794038)

  • 21. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.
    Denardi LB; Keller JT; Oliveira V; Mario DAN; Santurio JM; Alves SH
    Mycopathologia; 2017 Oct; 182(9-10):819-828. PubMed ID: 28493006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Sun L; Wan Z; Li R; Yu J
    J Med Microbiol; 2019 Nov; 68(11):1664-1670. PubMed ID: 31553302
    [No Abstract]   [Full Text] [Related]  

  • 28. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
    Lee JS; Shin JH; Lee K; Kim MN; Shin BM; Uh Y; Lee WG; Lee HS; Chang CL; Kim SH; Shin MG; Suh SP; Ryang DW
    Yonsei Med J; 2007 Oct; 48(5):779-86. PubMed ID: 17963334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
    Marangon FB; Miller D; Giaconi JA; Alfonso EC
    Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging pathogen Trichoderma spp.
    Kratzer C; Tobudic S; Schmoll M; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2006 Nov; 58(5):1058-61. PubMed ID: 16987867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Tonui J; Mureithi M; Jaoko W; Bii C
    Pan Afr Med J; 2021; 38():227. PubMed ID: 34046132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Gao L; Sun Y; Yuan M; Li M; Zeng T
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253207
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
    Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
    J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small molecules restore azole activity against drug-tolerant and drug-resistant
    Alabi PE; Gautier C; Murphy TP; Gu X; Lepas M; Aimanianda V; Sello JK; Ene IV
    mBio; 2023 Aug; 14(4):e0047923. PubMed ID: 37326546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.
    Chamilos G; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2006 Jan; 50(1):96-103. PubMed ID: 16377673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.